Overview

A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer

Status:
Active, not recruiting

Trial end date:
2021-10-29

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to evaluate the safety and efficacy of abemaciclib in combination with pembrolizumab in participants with advanced non-small cell lung cancer (NSCLC) or hormone receptor positive (HR+), human epidermal growth factor receptor negative (HER2-) breast cancer.

Phase:

Phase 1

Details

Lead Sponsor:

Eli Lilly and Company

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Anastrozole
Pembrolizumab